Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
May 23, 2019 8:30 AM EDT
20ᵀᴴ Annual B. Riley FBR Institutional Investor Conference
Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will participate in a fireside chat presentation with Mayank Mamtani, B. Riley FBR research analyst
Beverly Hills
Archived Events
Date Event Details
Sep 16, 2018 12:15 PM CDT
European Respiratory Society International Congress 2018
September 16, 12:15 p.m. CEST – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
Sep 7, 2018 5:45 PM EDT
18th World Gastroenterologists Summit
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”
Sep 4, 2018
Annual B. Riley FBR Healthcare Conference
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions
Aug 7, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Third Quarter Results
Jun 29, 2018 3:45 PM PDT
27th Annual Alpha-1 National Education Conference
San Francisco, CA
Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
Jun 20, 2018 9:00 AM EDT
JMP Securities Life Science Conference
New York, NY
Bruce Given, M.D., will present a corporate overview
Jun 15, 2018 2:15 PM EDT
Global Hepatitis Summit 2018
Toronto
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
Jun 8, 2018 5:30 PM +08
The Science of HBV Cure 2018
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”
Jun 6, 2018 3:30 PM EDT
Jefferies 2018 Global Healthcare Conference
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
Jun 6, 2018 5:55 PM CEST
41st European Cystic Fibrosis Conference
Belgrade, Serbia
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled,“Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”